FMT Novel Autism Therapy Highest Success Rate
AUTISM IS NOT A DISEASE, IT'S A TEMPORARY PHASE IN THE LIFE OF A CHILD, IF IT IS TREATED TIMELY
1) FMT in Children With Autism
Full Recovery From Autism - Absolute Recovery From Autism
2) FMT has been shown to resolve 80%+ of Autism cases
symptom reductions of up to 50% were maintained two years after fecal transplants
3) 84% improvement in the core ASD symptoms of language, social interaction and behavior even after two years.
4) Over three-quarters of severe cases were reduced to mild, moderate, or below the scale.
5) Fecal transplants can help treat Inflammatory Bowel Disease (IBD) in up to 77% of cases.
FMT Relieves Autism
Manipulation of the gut microbiota by fecal microbiota transplantation (FMT) was recently shown to be a promising therapy for the treatment of various diseases. Here, we performed a clinical trial to evaluate the effect of FMT on gastrointestinal (GI) and ASD symptoms and gut microbiota alterations in children with ASD. We found that there was a large difference in baseline characteristics of behavior, GI symptoms, and gut microbiota between children with ASD and typically developing (TD) control children.
FMT could improve GI symptoms and ASD symptoms without inducing any severe complications. Similarly, FMT significantly changed the serum levels of neurotransmitters.
Our data suggest that FMT might be a promising therapeutic strategy to improve the GI and behavioral symptoms of patients with ASD, possibly due to its ability to alter gut microbiota and highlight a specific microbiota intervention that targets Eubacterium coprostanoligenes that can enhance the FMT response
Assessments of Autism and Related Symptoms
Autism and ASD related symptoms were assessed by the Childhood Autism Rating Scale (CARS), Social Responsiveness Scale (SRS) and Autism Behavior Checklist (ABC). The CARS is a 15-item scale that can be used to both diagnose ASD and assess the overall severity of the symptoms. The ABC assesses problem behaviors in five areas that are common in children with ASD, including irritability, lethargy, stereotypy, hyperactivity, and inappropriate speech. Additionally, we assessed parents’ levels of anxiety with the Self-Rating Anxiety Scale (SAS). The SAS is a 20-item scale that measures the severity of anxiety in parents of children with ASD.
The CARS, ABC, SRS, and SAS were administered at baseline (week 0), at the end of treatment (week 4), and at the end of the observation period (week 12).